Pharmaceutical News

RSS

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen.

11 Feb 2010

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd., has received new drug registration approval from the State Food and Drug Administration ("SFDA") to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of Influenza A and Influenza B. Zanamivir is marketed globally by GlaxoSmithKline under the trade name Relenza.

11 Feb 2010

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

Indiana's contract pharmaceutical research and manufacturing companies continued to expand in 2009, despite challenges in the biopharmaceutical contract service sector due to the downturn in the economy, the prospect of healthcare reform and other market developments.

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Drug used to treat parasites in animals may offer new treatment for river blindness, study finds

"Closantel, an older drug used to treat a parasitic liver disease in animals, may prove effective at combating river blindness in humans, a major cause of infection-related blindness, U.S. researchers said on Monday," Reuters reports (Steenhuysen, 2/8).

10 Feb 2010

$TZD drug may increase fracture risk in older women$

TZD drug may increase fracture risk in older women

A Henry Ford Hospital study finds women with type 2 diabetes who take a commonly prescribed class of medications to treat insulin resistance may be at a higher risk for developing bone fractures.

10 Feb 2010

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

10 Feb 2010

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)—the leading therapy in the psoriasis drug market in 2008—will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Majority of parents worry about safety of H1N1 vaccine

Ask any health professional who cares for children and they will tell you: When H1N1 flu hits, it can be very severe. In the last four months of 2009, nearly 240 children died in the United States from H1N1 flu—more than three times as many child deaths as in a typical non-H1N1 flu season.

10 Feb 2010

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.

10 Feb 2010

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.

10 Feb 2010

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Glissandra Skincare™ Inc., dedicated to the research, development, and manufacturing of anti-aging skincare products, announced it has signed its first distributorship agreement granting Enchanted Meadow the rights to distribute Glissandra to its more than 2000 spa and gift industry retailers throughout the US and Canada.

10 Feb 2010

Pivotal Research to study investigational drug for menstrual cramps

A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

10 Feb 2010

New method may help assess impact and cost-effectiveness of flu vaccination campaigns

A new study (doi:10.1016/j.vaccine.2010.01.002), published by Elsevier this month in Vaccine (http://www.elsevier.com/locate/vaccine) describes a new method that assesses the impact and cost-effectiveness of a range of vaccination options.

10 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

Pharmaceutical News

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Simcere Pharmaceutical Group subsidiary receives Chinese SFDA approval for Zanamivir

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

Micromet outlines the design of registration study for blinatumomab in ALL

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

CINJ researchers develop new vaccine strategy for pancreatic cancer

Drug used to treat parasites in animals may offer new treatment for river blindness, study finds

TZD drug may increase fracture risk in older women

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Medicinal chemistry paper related to the discovery of CUDC-101 published

Study shows more women die of heart disease each year than men

Majority of parents worry about safety of H1N1 vaccine

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Pivotal Research to study investigational drug for menstrual cramps

New method may help assess impact and cost-effectiveness of flu vaccination campaigns

New research suggests closantel drug may be useful in combating river blindness

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News